Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Clinical trials sponsored by Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd., explained in plain language.
A Chinese pharmaceutical company, subsidiary of Fosun Pharma.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug FXS5626 put to the test: will it affect the Heart's rhythm? Results expected Sep 2026 (estimated)
- New pill could tame eye inflammation without needles Results expected Feb 2027 (estimated)
- New drug FXS887 enters first human tests for tough cancers Results expected Apr 2027 (estimated)
- New drug aims to reduce kidney damage in IgAN patients Results expected Sep 2027 (estimated)
-
New drug combo takes aim at KRAS-Mutant lung cancer
Disease control Recruiting nowThis Phase 2 trial tests whether combining two oral drugs, luvometinib and anlotinib, can shrink tumors in people with KRAS-mutated non-small cell lung cancer that has spread and stopped responding to prior treatment. About 48 adults will receive different dose combinations. The …
Phase 2 • Sponsor: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New pill could tame eye inflammation without needles
Disease control Recruiting nowThis study tests an oral medication called FXS5626 in 40 adults with active non-infectious uveitis, a condition causing inflammation inside the eye. The goal is to see if the drug can control the disease better than a placebo, reducing the need for other treatments. Participants …
Phase 2 • Sponsor: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC